Market Overview

UPDATE: Barclays Downgrades Ariad Pharmaceuticals Following News of Iclusig Clinical Hold

Related ARIA
GNC, Southern Copper And Others Insiders Have Been Buying
ARIAD Announces Commercial Agreement for Iclusig (Ponatinib) in Israel

In a report published Thursday, Barclays analyst Ying Huang downgraded the rating on Ariad Pharmaceuticals (NASDAQ: ARIA) from Overweight to Underweight, and lowered the price target from $25.00 to $4.00.

In the report, Barclays noted, “We are downgrading ARIA to UW from OW and reducing our price target to $4 from $25, on higher risk of Iclusig not receiving FDA approval as a front-line therapy for chronic myeloid leukemia (CML) and reduced peak sales in second-line treatment given safety concerns around cardiovascular, cerebrovascular, and peripheral vascular thrombosis. We see risk/reward skewed to the downside at current levels.”

Ariad Pharmaceuticals closed on Wednesday at $5.83.

Latest Ratings for ARIA

DateFirmActionFromTo
Aug 2014CitigroupMaintainsSell
Aug 2014JMP SecuritiesMaintainsMarket Outperform
Jun 2014UBSMaintainsNeutral

View More Analyst Ratings for ARIA
View the Latest Analyst Ratings

Posted-In: Barclays Capital Ying HuangAnalyst Color Downgrades Analyst Ratings

 

Related Articles (ARIA)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters